KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovoCure (NVCR) Non-Current Debt (2016 - 2025)

Historic Non-Current Debt for NovoCure (NVCR) over the last 11 years, with Q3 2025 value amounting to $194.6 million.

  • NovoCure's Non-Current Debt rose 10035.1% to $194.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $194.6 million, marking a year-over-year increase of 10035.1%. This contributed to the annual value of $97.3 million for FY2024, which is N/A changed from last year.
  • NovoCure's Non-Current Debt amounted to $194.6 million in Q3 2025, which was up 10035.1% from $97.6 million recorded in Q2 2025.
  • Over the past 5 years, NovoCure's Non-Current Debt peaked at $569.7 million during Q1 2024, and registered a low of $97.0 million during Q2 2024.
  • In the last 5 years, NovoCure's Non-Current Debt had a median value of $561.8 million in 2021 and averaged $414.1 million.
  • Per our database at Business Quant, NovoCure's Non-Current Debt skyrocketed by 27494.03% in 2021 and then plummeted by 8290.36% in 2024.
  • Quarter analysis of 5 years shows NovoCure's Non-Current Debt stood at $562.2 million in 2021, then rose by 0.59% to $565.5 million in 2022, then increased by 0.44% to $568.0 million in 2023, then crashed by 82.87% to $97.3 million in 2024, then surged by 100.04% to $194.6 million in 2025.
  • Its Non-Current Debt was $194.6 million in Q3 2025, compared to $97.6 million in Q2 2025 and $97.4 million in Q1 2025.